RESUMEN
AIMS: To validate a translated and culturally adapted version of the Morisky Medication Adherence Scale for use in Spanish population, and to examine the psychometric properties of this scale in patients with type 2 diabetes mellitus in Spain. DESIGN: This cross-sectional study was conducted in a single university hospital in Spain. Patients diagnosed with type 2 diabetes mellitus at least 1 year before inclusion, being treated with anti-diabetic medication were included. Intervention: We used the Spanish version of the scale to measure treatment adherence. Principal measurements: three level categorical scale is broken down into low adherence (score of < 6), medium adherence (score of 6 to < 8) and high adherence (score of 8). To validate the questionnaire, we measured internal consistency through Cronbach's α, confirmed construct validity through an exploratory principal component analysis and assessed test-retest reliability. RESULTS: 232 patients met the inclusion criteria. The Cronbach's α coefficient was 0.40 (95% CI 0.28-0.52). The exploratory principal component analysis showed three components. The intraclass correlation coefficient was 0.718 (95% CI 0.564-0.823). CONCLUSIONS: the Spanish version of the Morisky Medication Adherence scale showed low internal consistency, the exploratory factor analysis identified three dimensions, and the test-retest reliability was acceptable, therefore, psychometric properties of MMAS-8 are not suitable for measuring medication adherence in type 2 diabetes mellitus patients from Spain
OBJETIVO: Validar la herramienta de adherencia terapéutica de Morisky tras una adaptación cultural y lingüística para su uso en la población española, y examinar sus propiedades psicométricas en pacientes con diabetes mellitus tipo 2 en España. DISEÑO: Se realizó un estudio transversal en un hospital universitario en España. PARTICIPANTES: Se incluyeron pacientes diagnosticados de diabetes mellitus tipo 2 al menos un año antes del estudio y tratados con antidiabéticos orales. Intervención: Se utilizó la versión traducida de la escala para medir la adherencia al tratamiento. Mediciones principales: Nivel de adherencia categorizado a través de 3 escalas, baja (< 6 puntos), media (6 a < 8 puntos) o alta (8 puntos). La consistencia interna del cuestionario se evaluó a través del coeficiente α de Cronbach, y se realizó un análisis exploratorio de los componentes principales para confirmar la validez del constructo, y se evaluó la fiabilidad a través del test-retest. RESULTADOS: Doscientos treinta y dos pacientes cumplieron con los criterios de inclusión. El coeficiente α de Cronbach era 0,40 (IC 95%: 0,28-0,52). El análisis exploratorio mostró 3 componentes principales. El coeficiente de correlación intraclase era de 0,718 (IC 95%: 0,564-0,823). CONCLUSIONES: La versión adaptada de la escala de adherencia terapéutica de Morisky mostró una consistencia interna baja, el análisis factorial exploratorio identificó 3 dimensiones y la fiabilidad test-retest fue aceptable, por lo tanto, las propiedades psicométricas de MMAS-8 no son adecuadas para medir la adherencia a la medicación en pacientes con diabetes mellitus tipo 2 en España
Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Cumplimiento de la Medicación/psicología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/psicología , Encuestas y Cuestionarios/normas , Estudios Transversales , Psicometría , Reproducibilidad de los Resultados , Traducciones , Comparación Transcultural , EspañaRESUMEN
AIMS: To validate a translated and culturally adapted version of the Morisky Medication Adherence Scale for use in Spanish population, and to examine the psychometric properties of this scale in patients with type 2 diabetes mellitus in Spain. DESIGN: This cross-sectional study was conducted in a single university hospital in Spain. Patients diagnosed with type 2 diabetes mellitus at least 1 year before inclusion, being treated with anti-diabetic medication were included. INTERVENTION: We used the Spanish version of the scale to measure treatment adherence. PRINCIPAL MEASUREMENTS: three level categorical scale is broken down into low adherence (score of <6), medium adherence (score of 6 to <8) and high adherence (score of 8). To validate the questionnaire, we measured internal consistency through Cronbach's α, confirmed construct validity through an exploratory principal component analysis and assessed test-retest reliability. RESULTS: 232 patients met the inclusion criteria. The Cronbach's α coefficient was 0.40 (95% CI 0.28-0.52). The exploratory principal component analysis showed three components. The intraclass correlation coefficient was 0.718 (95% CI 0.564-0.823). CONCLUSIONS: the Spanish version of the Morisky Medication Adherence scale showed low internal consistency, the exploratory factor analysis identified three dimensions, and the test-retest reliability was acceptable, therefore, psychometric properties of MMAS-8 are not suitable for measuring medication adherence in type 2 diabetes mellitus patients from Spain.